DrugPatentWatch Database Preview
Patent: 6,723,338
» See Plans and Pricing
Summary for Patent: 6,723,338
| Title: | Compositions and methods for treating lymphoma |
| Abstract: | This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin\'s Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma. |
| Inventor(s): | Sarris; Andreas H. (Houston, TX), Cabanillas; Fernando (Houston, TX), Logan; Patricia M. (Vancouver, CA), Burge; Clive T. R. (Brentwood Bay, CA), Goldie; James H. (Vancouver, CA), Webb; Murray S. (Delta, CA) |
| Assignee: | Inex Pharmaceuticals Corporation (Burnaby, CA) Board of Regents, The University of Texas System (Austin, TX) |
| Application Number: | 09/541,436 |
| Patent Claims: | see list of patent claims |
Details for Patent 6,723,338
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | Start Trial | Inex Pharmaceuticals Corporation (Burnaby, CA) Board of Regents, The University of Texas System (Austin, TX) | 2019-04-01 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | Inex Pharmaceuticals Corporation (Burnaby, CA) Board of Regents, The University of Texas System (Austin, TX) | 2019-04-01 | RX | Orphan | search |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 002 | 1997-11-26 | Start Trial | Inex Pharmaceuticals Corporation (Burnaby, CA) Board of Regents, The University of Texas System (Austin, TX) | 2019-04-01 | RX | search | |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 001 | 1997-11-26 | Start Trial | Inex Pharmaceuticals Corporation (Burnaby, CA) Board of Regents, The University of Texas System (Austin, TX) | 2019-04-01 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 6,723,338
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 0059473 | Start Trial |
| World Intellectual Property Organization (WIPO) | 0202077 | Start Trial |
| World Intellectual Property Organization (WIPO) | 0202078 | Start Trial |
| United States of America | 2002110586 | Start Trial |
| United States of America | 2002119990 | Start Trial |
| United States of America | 2004071768 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
